Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizanlizumab in RVCL
NCT04611880Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2021
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of crizanlizumab in retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S), sponsored by Washington University School of Medicine. Primary endpoint: Change in the Percentage of White Matter Hyperintensity (WMH) Lesion Volume on FLAIR MRI at 1 year. Started Jan 2021; status: completed.
02
Drugs
crizanlizumab
03
Conditions
retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S)
Beyond the preview
Go deeper on NCT04611880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04611880.